Inhibikase Therapeutics, Inc. (IKT) News
Follow Inhibikase Therapeutics, Inc. (IKT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Inhibikase updates presentation, highlights Phase 3 IKT-001 timelines
Inhibikase updated its corporate presentation to highlight progress on the Phase 3 IKT-001 program and anticipated clinical timelines.
REGULATION | Sep 08, 2026, 08:43 PM UTC
L
Inhibikase Therapeutics Q2 EPS $(0.11), Inline
Inhibikase Therapeutics (NASDAQ: IKT ) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
EARNINGS | Aug 11, 2026, 08:16 PM UTC
L
IKT - Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
IKT - Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
EARNINGS | Aug 11, 2026, 08:01 PM UTC
L
IKT Inhibikase Therapeutics announces FDA orphan drug designation granted to ikt-001 for the treatment of pah
IKT Inhibikase Therapeutics announces FDA orphan drug designation granted to ikt-001 for the treatment of pah
REGULATION | Jul 23, 2026, 12:00 PM UTC
H
Danaher Posts Q2 Results, Joins Calix, Equifax And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining more than 1% on Tuesday. Shares of Danaher Corp (NYSE: DHR ) fell sharply in pre-market trading following second-quarter results. Danaher p
EARNINGS | Jul 21, 2026, 12:01 PM UTC
L
Inhibikase Therapeutics' treatment of PAH granted FDA orphan designation
Inhibikase...
REGULATION | Jul 16, 2026, 09:03 PM UTC